Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study

BACKGROUND: In ASPIRE, carfilzomib, lenalidomide, and dexamethasone (KRd) significantly improved progression-free survival (PFS) and response rates versus lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma. Per protocol, patients received KRd for a maximum of 18 cycles fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Dimopoulos, Meletios, Wang, Michael, Maisnar, Vladimir, Minarik, Jiri, Bensinger, William, Mateos, Maria-Victoria, Obreja, Mihaela, Blaedel, Julie, Moreau, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5883881/
https://www.ncbi.nlm.nih.gov/pubmed/29615082
http://dx.doi.org/10.1186/s13045-018-0583-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5883881/
https://www.ncbi.nlm.nih.gov/pubmed/29615082
http://dx.doi.org/10.1186/s13045-018-0583-7

Ejemplares similares